SCHEMBL13320309

SCHEMBL13320309

Cc1ccc(OCc2ccccc2F)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.65
PARP15 Q460N3 3/20 0.59
PARP10 Q53GL7 3/20 0.59
PARP14 Q460N5 1/20 0.59
TDP1 Q9NUW8 2/20 0.57
LMNA P02545 1/20 0.57
MAPT P10636 1/20 0.57
HTT P42858 1/20 0.57
NPC1 O15118 3/20 0.54
RAB9A P51151 3/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
CASP3 P42574 1/20 0.52
SENP8 Q96LD8 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52
IDO1 P14902 2/20 0.50
RECQL P46063 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38655920 1.00 MAOB (0.65) MAOBPARP15PARP10PARP14TDP1
SCHEMBL1549058 0.86 KCNH2 (0.55) MAOBLMNANPC1RAB9ASMN1; SMN2
SCHEMBL21340831 0.85 MAOB (0.65) MAOBPARP15PARP10PARP14TDP1
SCHEMBL12443168 0.85 PTPN1 (0.53) MAOBPARP15PARP10PARP14TDP1
SCHEMBL12423201 0.85 MAOB (0.69) MAOBPARP15PARP10PARP14TDP1
SCHEMBL15474227 0.85 MAOB (0.52) MAOBPARP15PARP10PARP14TDP1
SCHEMBL17644774 0.84 MAOB (0.68) MAOBPARP15PARP10PARP14TDP1
SCHEMBL14018700 0.84 MAOB (0.54) MAOBPARP15PARP10PARP14TDP1
SCHEMBL3625841 0.83 MAOB (0.67) MAOBPARP15PARP10PARP14TDP1
Hydrochloric Acid SCHEMBL28551904 0.82 MAOB (0.69) MAOBPARP15PARP10PARP14TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3819303-A1 GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE Shanghai Hutchison Pharmaceuticals Limited (CN) 2021-05-12 EP disclosed
WO-2020210485-A1 PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES BIOGEN MA INC. (US) 2020-10-15 WO disclosed
EP-2598482-B1 ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE ORYZON GENOMICS SA (ES) 2018-04-04 EP disclosed
US-9187437-B2 Substituted oxadiazole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2015-11-17 US disclosed
US-20130190361-A1 SUBSTITUTED OXADIAZOLE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2013-07-25 US disclosed
US-20100130583-A1 PROLINAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS GLAXO GROUP LIMITED (GB) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190361-A1 SUBSTITUTED OXADIAZOLE COMPOUNDS S1PR1, S1PR3, S1PR2 MAOB 1630/4885PARP15 1137/4885PARP10 1599/4885
US-20100130583-A1 PROLINAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS SCN1A, SCN3A, SCN2A MAOB 3647/4885PARP15 1604/4885PARP10 1534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.